Natixis Madrigal Pharmaceuticals, Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$120.4 - $237.13 $5,418 - $10,670	-45 Reduced 4.99%	857 $198,000
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $131,728 - $203,653	902 New	902 $131,000
Q1 2023 May 12, 2023	BUY	$231.06 - $307.08 $256,245 - $340,551	1,109 New	1,109 $268,000
Q4 2022 Feb 13, 2023	BUY	$58.39 - $296.54 $68,783 - $349,324	1,178 New	1,178 $341,000
Q2 2021 Aug 13, 2021	SELL	$97.2 - $137.59 $2.14 Million - $3.03 Million	-22,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$108.54 - $125.2 $3.44 Million - $3.97 Million	-31,722 Reduced 59.05%	22,000 $2.57 Million
Q4 2020 Feb 12, 2021	SELL	$110.06 - $133.7 $2.8 Million - $3.4 Million	-25,412 Reduced 32.11%	53,722 $5.97 Million
Q3 2020 Nov 12, 2020	BUY	$99.78 - $124.21 $7.9 Million - $9.83 Million	79,134 New	79,134 $9.4 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.76B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.